Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

Real-time Quote. Real-time Tradegate - 02/23 03:05:05 pm
80.675 EUR   +0.50%
02:53p INTERCEPT PHARM : ICPT) Files An 8-K Results of Operations and Finan..
02/20 SANOFI : Disclosure of trading in own shares
02/17 SANOFI : JHL Biotech Form Strategic Partnership
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Sanofi's Genzyme Says MS Drug Lemtrada Shows More Trial Success

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2012 | 09:39pm CET

Genzyme, the U.S. biotechnology unit of France's Sanofi SA (SNY), Tuesday said latest results from a late-stage clinical study showed its multiple sclerosis drug Lemtrada significantly reduced relapses and any worsening of the condition, and in some cases showed a reversal in disability.

In a Phase III trial called CARE-MS II involving 840 patients, the relapse rate was reduced by 49%, compared with an older drug called Rebif, or subcutaneous interferon beta-1a, which is sold by German rival Merck KGaA (>> Merck KGaA).

The company said 65% of patients treated with Lemtrada were relapse-free after two years into the study, compared with 47% treated with Rebif.

Genzyme is developing the drug, also known as alemtuzumab, in collaboration with German drug maker Bayer AG (>> Bayer AG), and Sanofi aims to launch the drug by the end of next year. Multiple sclerosis is a chronic disease that attacks the central nervous system.

"We believe these ground-breaking results from CARE-MS II, including reversal of disability accumulation in some patients, achieved over the standard therapy Rebif, provide a message of hope for people living with MS," said David Meeker, Genzyme's CEO, said in a statement, adding: "We are on track to submit alemtuzumab for review to U.S. and EU regulatory authorities in the second quarter of this year."

In the CARE-MS II trial, alemtuzumab was given as an injection eight times over the course of the two-year study. The first treatment course of alemtuzumab was administered on five consecutive days, and the second course was administered on three consecutive days 12 months later. Rebif was administered by injection three times per week, each week, throughout the two years of study.

Sanofi, which is struggling with patent expiries on its blockbuster drugs, bought Genzyme in February 2011 in a bid to widen its research net.

--By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

Stocks mentioned in the article : Merck KGaA, Bayer AG
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
02:53p INTERCEPT PHARMACEUTICALS, INC. (NAS : ICPT) Files An 8-K Results of Operations ..
02/20 SANOFI : Disclosure of trading in own shares
02/17 SANOFI : JHL Biotech Form Strategic Partnership
02/16 REGENERON PHARMACEUTICALS : Appeals Court Grants Stay of Permanent Injunction fo..
02/16 SANOFI : Researchers' Work from Sanofi Pasteur Focuses on Hepatitis (Immunogenic..
02/16 SANOFI : Researchers from Sanofi Report Recent Findings in Osteoarthritis (I kap..
02/16 SANOFI : brings Toujeo to local market
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/16 IPSEN : Acquires Five Sanofi Consumer Healthcare Products
02/15 SANOFI -FEBRUARY 4&15 : World Cancer Days
More news
Sector news : Pharmaceuticals - NEC
11:51aDJGlaxoSmithKline Reports Positive Study Results for Asthma Drug
10:23aDJPURETECH HEALTH : Appoints Atul Pande as Chief Medical Officer
08:49aDJBAYER : Financing Plan Will Raise Equity First Then Bonds -- WSJ
08:49aDJBAYER : CEO Still Upbeat on Deal -- WSJ
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/22 Should Merck, BMS Fear Roche's Drug Becoming The I-O King?
02/21 PROTALIX BIOTHERAPEUTICS : New Institutional Ownership Swells Ahead Of Major Cat..
02/21 A Time To Buy Novo Nordisk
02/21 HEPATITIS B MARKET : Emerging Players Could Make The Difference
02/17 MannKind - Afrezza Sales Slip As New Sales Force Starts
Advertisement
Financials (€)
Sales 2017 36 457 M
EBIT 2017 9 209 M
Net income 2017 5 873 M
Debt 2017 4 692 M
Yield 2017 3,81%
P/E ratio 2017 14,79
P/E ratio 2018 16,83
EV / Sales 2017 2,97x
EV / Sales 2018 2,84x
Capitalization 103 711 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 82,3 €
Spread / Average Target 2,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI4.38%109 481
JOHNSON & JOHNSON3.86%325 158
ROCHE HOLDING LTD.5.98%210 992
PFIZER INC.3.51%203 836
NOVARTIS AG3.51%202 566
MERCK & CO., INC.11.23%180 014
More Results